Sameerah Ibtisam Rehmani, MBBS

Sameerah Rehmani practices at Sentara Obici Hospital in Suffolk, Virginia, part of Sentara Health.

Sameerah Rehmani's NPI, 1245750538, was assigned on June 27, 2017. Sameerah Rehmani holds Virginia license 0101268259.

Sameerah Rehmani's primary practice is Sentara Obici Hospital, at 2800 Godwin Boulevard, Suffolk, VA 23434 in Suffolk City. The practice phone is (757) 934-4000.

Sameerah Rehmani's primary practice is Sentara Obici Hospital in Suffolk, Virginia, part of Sentara Health. Sameerah Rehmani is also affiliated with Sentara Norfolk General Hospital. The medical group on file is Powerback Rehabilitation. Dmand AI also links Sameerah Rehmani to 3 more hospitals, 2 home health agencies, 1 group practice or clinic, 1 hospital outpatient department, 1 therapy and rehab clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Sameerah Rehmani practices, 10 sites in all. Vendor and product names are available with a free account.

Internal medicine is Sameerah Rehmani's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Sameerah Rehmani is licensed in Virginia.

CMS data shows 1,898 Medicare services from Sameerah Rehmani across 14 procedure codes in 2024, for 310 Medicare patients. Medicare paid $114,236 for them. Every service was in an office.

CMS counts 310 Medicare patients who saw Sameerah Rehmani in 2024. The largest group is 65 to 74, with 153 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.04, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Sameerah Rehmani's median patient age at 61, with 71% women.

In 2024, Sameerah Rehmani wrote 4,319 Medicare Part D claims for 330 patients. 86% of them were for generic drugs. CMS names the drug for 3,709 of them, across 82 drugs with 11 or more claims each, at $343,541 in total drug cost. In 2023, CMS named 4,189 claims across 91 drugs.

Sameerah Rehmani accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Sameerah Rehmani, published from 2019 to 2021. 2021 was the busiest year, with 3. Sameerah Rehmani has published most often in BMJ Case Rep. Sameerah Rehmani's most frequent co-authors are Saad Jamil, MD, Saad Bin Jamil and Arjet Gega, MD.

CMS Open Payments shows 164 general payments to Sameerah Rehmani from 30 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 100% of the total. Novo Nordisk Inc paid the most, $588.